Sporadic dementia of Alzheimer's type induced by streptozotocin promotes anxiogenic behavior in mice

Behavioural Brain Research

Volumn 223, Issue 1, 2011, Pages 1-6

  Pinton, Simone ^a   da Rocha, Juliana Trevisan ^a   Gai, Bibiana Mozzaquatro ^a   Nogueira, Cristina Wayne ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Anxiety like behavior; Anxiogenic; Sporadic dementia of Alzheimer's type; Streptozotocin

Indexed keywords

STREPTOZOCIN;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; CONTROLLED STUDY; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; LATENT PERIOD; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TASK PERFORMANCE;

ALZHEIMER DISEASE; ANIMALS; ANXIETY; AVOIDANCE LEARNING; BLOOD GLUCOSE; CHOICE BEHAVIOR; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAVENTRICULAR; MALE; MAZE LEARNING; MICE; MOTOR ACTIVITY; STREPTOZOCIN; TIME FACTORS;

EID: 79955676717     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2011.04.014     Document Type: Article

References (51)

1. WHO. Global burden of neurological disorders: estimates and projections. Switzerland, 2006; p. 281-304.
2. Cha J.H.J., Farrel L.A., Ahmed S.F., Frey A., Hsia-Ashe K.K., Young A.B., et al. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis 2001, 8:90-102.
3. Blennow K., de Leon M.J., Zetterberg H. Alzheimer's disease. Lancet 2006, 368:387-403.
4. WHO, Mental and Neurological Disorders. Fact Sheet, 2001; 265.
5. Vloeberghs E., Van Dam D., Franck F., Staufenbiel M., de Deyn P.P. Mood and male sexual behaviour in the APP23 model of Alzheimer's disease. Behav Brain Res 2007, 180:146-151.
6. Geda Y.E., Roberts R.O., Knopman D.S., Petersen R.C., Christianson T.J., Pankratz V.S., et al. The prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: a population-based study. Arch Gen Psychiatry 2008, 65:1193-1198.
7. Lester-coll N., Rivera E.J., Soscia S.J., Doiron K., Wands J.R., de La Monte S.M. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's diseases. J Alzheimer's Dis 2006, 9:13-33.
8. Grünblatt E., Salkovic-Petrisic M., Osmanovic J., Riederer P., Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 2007, 101:757-770.
9. Lannert H., Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 1998, 112:1199-1208.
10. Ishrat T., Parveen K., Khan M.M., Khuwaja G., Khan M.B., Yousuf S., et al. Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's disease. Brain Res 2009, 1281:117-127.
11. Tota S., Kamat P.K., Awasthi H., Singh N., Raghubir R., Nath C., et al. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin. Behav Brain Res 2009, 199:235-240.
12. Pinton S., da Rocha J.T., Zeni G., Nogueira C.W. Organoselenium improves memory decline in mice: involvement of acetylcholinesterase activity. Neurosci Lett 2010, 472:56-60.
13. España J., Giménez-Llort L., Valero J., Miñano A., Rábano A., Rodriguez-Alvarez J., et al. Intraneuronal β-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry 2010, 67:513-521.
14. Pamplona F.A., Pandolfo P., Duarte F.S., Takahashi R.N., Prediger R.D.S. Altered emotionality leads to increased pain tolerance in amyloid β (Aβ1-40) peptide-treated mice. Behav Brain Res 2010, 212:96-102.
15. Tabuchi M., Yamaguchi T., Iizuka S., Imamura S., Ikarashi Y., Kase Y. Ameliorative effects of yokukansan, a traditional Japanese medicine, on learning and non-cognitive disturbances in the Tg2576 mouse model of Alzheimer's disease. J Ethnopharmacol 2009, 122:157-162.
16. Tong Y., Xu Y., Scearce-Levie K., Ptáček L.J., Fu Y. COL25A1 triggers and promotes Alzheimer's disease-like pathology in vivo. Neurogenetics 2010, 11:41-52.
17. Haley T.J., McCormick W.G. Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. Br J Pharmacol Chemother 1957, 12:12-15.
18. Laursen S.E., Belknap J.K. Intracerebroventricular injections in mice: some methodological refinements. J Pharmacol Methods 1986, 16:355-357.
19. Sakaguchi M., Koseki M., Wakamatsu M., Matsumura E. Effects of systemic administration of β-casomorphin-5 on learning and memory in mice. Eur J Pharmacol 2006, 530:81-87.
20. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985, 14:149-167.
21. Clénet F., Bouyon E., Hascoet M., Bourin M. Light/dark cycle manipulation influences mice behavior in the elevated plus maze. Behav Brain Res 2006, 166:140-149.
22. Costall B., Jones B.J., Kelly M.E., Naylor R.J., Tomkins D.M. Exploration of mice in a black and white box: validation as a model of anxiety. Pharmacol Biochem Behav 1989, 32:777-785.
23. Crawley J.N., Goodwin F.K. Preliminary report of a simple animal behavior for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 1980, 13:167-170.
24. Walsh R.N., Cummins R.A. The open-field test: a critical review. Psychol Bull 1976, 83:482-504.
25. Chung J.A., Cummings J.L. Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease. Neurol Clin 2000, 18:829-846.
26. Lapiz-Bluhm M.D.S., Bondi C.O., Doyen J., Rodriguez G.A., Bédard-Arana T., Morilak D.A. Behavioural assays to model cognitive and affective dimensions of depression and anxiety in rats. J Neuroendocrinol 2008, 20:1115-1137.
27. Holmes A., Iles J.P., Mayell S.J., Rodgers R.J. Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behav Brain Res 2001, 122:159-167.
28. Hascoët M., Bourin M., Dhonnchadha B.A. The mouse light-dark paradigm: A review. Prog Neuropsychopharmacol Biol Psychiatry 2001, 25:141-166.
29. Kilfoil T., Michel A., Montgomery D., Whiting R.L. Effects of anxiolytic and anxiogenic drugs on exploratory activity in a simple model of anxiety in mice. Neuropharmacology 1989, 28:901-905.
30. Tanji H., Ootsuki M., Matsui T., Maruyama M., Nemoto M., Tomita N., et al. Dementia caregiver's burdens and use of public services. Geriatr Gerontol Int 2005, 5:94-98.
31. Plaschke K., Hoyer S. Action of the diabetogenic drug streptozotocin on glycolytic and glycogenolytic metabolism in adult rat brain cortex and hippocampus. Int J Dev Neurosci 1993, 11:477-483.
32. Sharma B., Singh N., Singh M. Modulation of celecoxib- and streptozotocin induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. J Psychopharmacol 2008, 22:162-171.
33. Saxena G., Singh S.P., Agrawal R., Nath C. Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 2008, 581:283-289.
34. Agrawal R., Mishra B., Tyagi E., Nath C., Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 2010, 61:247-252.
35. Zhao W.Q., Chen H., Quon M.J., Alkon D.L. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 2004, 490:71-81.
36. Akanmu M.A., Nwabudike N.L., Ilesanmi O.R. Analgesic, learning and memory and anxiolytic effects of insulin in mice. Behav Brain Res 2009, 196:237-241.
37. Marks D.R., Tucker K., Cavallin M.A., Mast T.G., Fadool D.A. Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci 2009, 29:6734-6751.
38. Anagnostaras S.G., Maren S., Sage J.R., Goodrich S., Fanselow M.S. Scopolamine and Pavlovian fear conditioning in rats: dose-effect analysis. Neuropsychopharmacology 1999, 21:731-744.
39. Klinkenberg I., Blokland A. The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 2010, 34:1307-1350.
40. Smythe J.W., Bhatnagar S., Murphy D., Timothy C., Costall B. The effects of intrahippocampal scopolamine infusions on anxiety in rats as measured by the black-white box test. Brain Res Bull 1998, 45:89-93.
41. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: an update. Exp Gerontol 2000, 35:1363-1372.
42. Henneberg N., Hoyer S. Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)?. Arch Gerontol Geriatr 1995, 21:63-74.
43. Raskind M.A., Wilkinson C.W., Peskind E.R. Aging and Alzheimer's disease. Horm Brain Behav 2002, 5:637-664.
44. Arsenault-Lapierre G., Chertkow H., Lupien S. Seasonal effects on cortisol secretion in normal aging, mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 2010, 31:1051-1054.
45. Tota S., Awasthi H., Kamat P.K., Nath C., Hanif K. Protective effect of quercetin against intracerebral streptozotocin induced reduction in cerebral blood flow and impairment of memory in mice. Behav Brain Res 2010, 209:73-79.
46. Sharma M., Gupta Y.K. Intracerebroventricular injection of streptozotocin in rats produces both oxidative stress in the brain and cognitive impairment. Life Sci. 2001, 68:1021-1029.
47. Kumar M.H.V., Gupta Y.K. Effect of centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. Clin Exp Pharmacol Physiol 2003, 30:336-342.
48. Ishrat T., Khan M.B., Hoda M.N., Yousuf S., Ahmad M., Ansari M.A., et al. Coenzyme Q10 modulates cognitive impairment against intracerebroventricular injection of streptozotocin in rats. Behav Brain Res 2006, 171:9-16.
49. Pathan A.R., Viswanad B., Sonkusare S.K., Ramarao P. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 2006, 79:2209-2216.
50. Saxena G., Singh S.P., Pal R., Singh S., Pratap R., Nath C. Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochem Behav 2007, 86:797-805.
51. Deshmukh R., Sharma V., Mehan S., Sharma N., Bedi K.L. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol 2009, 620:49-56.